STOCK TITAN
  1. Home
  2. News
  3. DCPH

Deciphera Pharmaceuticals Inc - DCPH STOCK NEWS

Welcome to our dedicated news page for Deciphera Pharmaceuticals (Ticker: DCPH), a resource for investors and traders seeking the latest updates and insights on Deciphera Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Deciphera Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Deciphera Pharmaceuticals's position in the market.

News
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
Rhea-AI Summary
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) management team to participate in virtual fireside chat at JMP Securities Hematology and Oncology Summit. Live webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
conferences
-
News
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) will participate in fireside chats at three investor conferences in November 2023. Live webcasts will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
conferences
-
News
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
Rhea-AI Summary
Deciphera Pharmaceuticals, Inc. reported total revenue of $43.3 million in Q3 2023, with net product revenue for QINLOCK increasing by 29% to $41.8 million compared to Q3 2022. The company also announced positive top-line results for the MOTION Phase 3 study of vimseltinib, an investigational treatment for TGCT. QINLOCK was successfully launched in Italy, and the company expects to submit a New Drug Application (NDA) with the FDA in Q2 2024. Deciphera reported a net loss of $49.6 million for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.54%
Tags
earnings
News
Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT
Rhea-AI Summary
Deciphera Pharmaceuticals announced positive top-line results from the MOTION Phase 3 study of vimseltinib in patients with TGCT. The study met the primary endpoint with an objective response rate (ORR) of 40% compared to 0% for placebo. All key secondary endpoints were also met, including ORR by Tumor Volume Score (TVS) of 67% vs. 0%. Updated results from the Phase 1/2 study showed an ORR of 72% (Phase 1) and 64% (Phase 2 Cohort A) with median treatment durations of 25.1 months (Phase 1) and 21.0 months (Phase 2 Cohort A). The treatment was well-tolerated with no evidence of hepatotoxicity. The company expects to submit a New Drug Application (NDA) in Q2 2024 and a Marketing Authorisation Application (MAA) in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.54%
Tags
clinical trial
-
News
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Deciphera Pharmaceuticals grants stock options and RSUs to new Chief Scientific Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Deciphera Pharmaceuticals grants stock options and restricted stock units to new Chief Technical Officer Kevin Brodbeck.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.18%
Tags
earnings
-
News
Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
management
-
News
Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023
Rhea-AI Summary
Deciphera Pharmaceuticals (NASDAQ: DCPH) will report its Q2 2023 financial results on August 9, 2023. A live conference call and webcast will be held to discuss the results and provide a corporate update. The webcast link can be accessed via the Company's website. A replay will be available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
earnings
News
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
conferences clinical trial
Stock DCPH logo
Deciphera Pharmaceuticals Inc

Nasdaq:DCPH

DCPH Rankings

#2283 Ranked by Market Cap
#4207 Ranked by Stock Gains
N/A Ranked by Dividends

DCPH Stock Data

1.22B
41.33M
30.49%
73.45%
7.5%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Waltham

About DCPH

deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.